Uveal melanoma: Current evidence on prognosis, treatment and potential developments

Gelmi, Maria Chiara; Jager, Martine J.

doi:10.1016/j.apjo.2024.100060

Asia-Pacific Journal of Ophthalmology

2024

DOI: 10.1016/j.apjo.2024.100060

|View full text |Cite

Uveal melanoma: Current evidence on prognosis, treatment and potential developments

Maria Chiara Gelmi,

Martine J. Jager

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication

Swords,

Kennedy,

Tonelotto

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common primary intraocular tumour in adults. Local resection, radiation therapy, and enucleation are the current first-line, primary UM treatments. However, regardless of the treatment received, around 50% of UM patients will develop metastatic disease within five to 7 years. In the largest published series of unselected patients with metastatic UM (mUM), the median survival time after diagnosis of metastasis was 3.6 months, with less than 1% of patients surviving beyond 5 years. Approved drugs for treatment of mUM include systemic treatment with tebentafusp-tebn or isolated hepatic perfusion (IHP) with melphalan. However, these drugs are only available to a subset of patients and improve survival by only a few months, highlighting the urgent need for new mUM treatments. Accurately predicting which patients are at high risk for metastases is also crucial. Researchers are developing gene expression signatures in primary UM to create reliable prognostic models aimed at improving patient follow-up and treatment strategies. In this review we discuss the evidence supporting ferroptosis, a non-apoptotic form of cell death, as a potential novel treatment target and prognosticator for UM.

show abstract

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication

Swords,

Kennedy,

Tonelotto

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Uveal melanoma: Current evidence on prognosis, treatment and potential developments

Cited by 1 publication

References 140 publications

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication

Contact Info

Product

Resources

About